Premium
Thromboxane Synthetase Inhibition: Potential Therapy in Migraine
Author(s) -
Joseph Rajiv,
Steiner J.T.,
Poole C.J.M.,
Littlewood J.,
Rose E Clifford
Publication year - 1985
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/j.1526-4610.1985.hed2504204.x
Subject(s) - migraine , thromboxane , radioimmunoassay , medicine , platelet , thromboxane b2 , regimen
SYNOPSIS Sixteen patients with migraine were treated prophylactically for 3 months with dazoxiben, a specific thromboxane synthetase inhibitor, in an open study, Frequency of all attacks was reduced by more than 50% in 7 patients, and of severe attacks in 8 of 10 patients who initially suffered severe attacks. Reductions in thromboxane B 2 levels measured at intervals during treatment by radioimmunoassay may have reflected standards of compliance with the 6‐hourly treatment regimen. However, a relationship emerged between thromboxane reduction and clinical response, with significantly greater reductions observed in patients who reported good symptomatic relief. This appears to support the hypothesis that platelet activation features in migraine causation.